Timothy Leary (1920–1996) is one of the most recognisable names in the history of psychedelics, and one of the most argued about. Before he became a counterculture figure, he was a clinical psychologist at Harvard, and his route into that world began with a plate of mushrooms in Mexico. Psilocybin, the compound at the centre of his later Harvard research, arrived in his lab as a pharmaceutical product rather than a mushroom. This page sets out what is documented about Leary’s early research, how it ended, and where it sits in the wider story. It also corrects a common mix-up: Leary was a psychologist, not a mycologist, and his Harvard research did not involve studying fungi at all.
From Wasson’s Article to Cuernavaca
The chain of events starts with R. Gordon Wasson. In May 1957, Life magazine published his account of taking part in a Mazatec mushroom ceremony in Oaxaca, which introduced a mass audience to the idea of “magic mushrooms”. A year later, the Sandoz chemist Albert Hofmann identified and named the active compounds, psilocybin and psilocin. Mushly’s overview of psilocybin mushrooms in history covers that period in more detail.
In August 1960, Leary travelled to Cuernavaca, Mexico, with a colleague who had already tried local mushrooms, and ate them himself for the first time. He later described it as the experience that changed the direction of his career (biography summary). The species he ate was not recorded in any scientific sense, which is typical of accounts from that era.
The Harvard Psilocybin Project
Back at Harvard, Leary and his colleague Richard Alpert, who later became known as Ram Dass, set up what became the Harvard Psilocybin Project. Crucially, they did not work with mushrooms. They ordered synthetic psilocybin, along with LSD, from Sandoz, the company where Hofmann worked (Harvard Psilocybin Project). The project’s interests were psychological and, increasingly, spiritual: how people described the experience, and whether the setting shaped it. Early sessions were loosely structured, and the researchers often took part themselves.
Two Studies That Are Still Discussed
Two pieces of work from the project are still cited, largely because later researchers went back and checked them.
- The Concord Prison Experiment (1961–1963). Leary’s team gave psilocybin to inmates at a Massachusetts prison, combined with group sessions, and reported that participants reoffended less often after release. In 1998, Rick Doblin published a follow-up based on criminal records for most of the original participants and concluded that the earlier claims of reduced reoffending were not supported (Doblin, Journal of Psychoactive Drugs, 1998; full text via MAPS).
- The Marsh Chapel or “Good Friday” Experiment (1962). Walter Pahnke, a graduate student at Harvard Divinity School, designed this study under Leary’s supervision. On Good Friday in April 1962, twenty divinity students attended a service at Boston University’s Marsh Chapel; half received psilocybin and half received niacin as an active placebo. Most of the psilocybin group described intense religious experiences (Marsh Chapel Experiment). Doblin’s later follow-up also noted problems with how the original study was run and reported.
Both studies are good examples of why this era is treated with caution today. The questions were interesting, but the methods were loose, and the researchers were often enthusiastic participants rather than neutral observers.
Controversy and the Exit From Harvard
Concerns inside Harvard surfaced in March 1962, when colleagues at the Center for Research in Personality said the drug sessions were being run in an unscientific and irresponsible way. Leary and Alpert agreed not to give drugs to undergraduates, and Massachusetts ruled that the substances could only be given with a physician present. In May 1963, Harvard dismissed Alpert for giving a drug to an undergraduate in breach of that agreement. Leary was relieved of his teaching duties and his salary was stopped for being absent from the university without permission (The Harvard Crimson, 1963).
From there, Leary moved on to an estate in Millbrook, New York, and into the public role he is best remembered for, including the slogan “turn on, tune in, drop out”. Psilocybin was placed under the strictest federal controls in the United States in 1970, and formal human research with it largely stopped for decades.
Leary and Mycology: Clearing Up the Confusion
Articles about Leary sometimes suggest that he contributed to fungal taxonomy or to the study of mushroom chemistry. There is no record of that. The names, species descriptions and distribution maps that mycologists rely on came from people such as Roger Heim, Gastón Guzmán and Rolf Singer, and the chemistry came from Hofmann and later analytical chemists. Leary’s contribution was to the psychology and cultural history of psychedelics, and his influence on how the public saw them was enormous, for better and for worse.
For the organisms themselves, the P. cubensis species guide covers the most widely known species, and the evolutionary mystery of psilocybin looks at why these fungi make the compound in the first place. If you are interested in looking at spores under a microscope, start with the microscopy primer. Legal status still varies widely, and the spore law guide for the USA and Canada summarises the current position.
Why the Story Still Matters
Leary’s Harvard years are a turning point in the history of psychedelic research. They show how quickly a promising line of inquiry can lose credibility when enthusiasm outruns method. They also explain much of the caution that shaped the field for the rest of the century. Reading the original sources alongside later follow-ups like Doblin’s is the best way to separate the documented history from the legend.
Mushroom spores are sold strictly for microscopy and research purposes only. The cultivation of psilocybin mushrooms is illegal in many jurisdictions.
